Dr. Lorraine Pelosof on the Growing Proportions of Non-Smokers With NSCLC

M. Michele Blackwood, MD, FACS, provided an overview of the significant advancements with personalized medicine with genomic testing in the breast cancer space.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell lung cancer, based on data from the phase 3 CheckMate 77T trial.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.

Savita Dandapani, MD, PhD, discussed combining radium-223 and SBRT for metastatic castration-sensitive prostate cancer.